Multiple Sclerosis (MS), which is the most prevalent immune-mediated inflammatory demyelinating disease affecting the Central Nervous System (CNS), has an estimated global incidence of 2,8 million individuals. Although its symptomatology is highly varied and unpredictable, depending on the lesions’ location in the CNS, visual impairments are among the most common manifestations. However, conventional methods for assessing and rehabilitating visuomotor competences are not sufficient to deliver objective assessments or personalized therapies. To address this gap, RehabVisual was adapted and its usability for MS patients was assessed. RehabVisual, developed in previous studies, aims to objectively assess visuomotor skills through an integrated low-cost eye tracking system. Before clinical application, a normative base was established using 50 healthy individuals for later comparison. The experimental group comprised 25 MS patients with and without confirmed visuomotor alterations. The protocol involved viewing three visual stimuli for later calculation of the mean Euclidean distance between the gaze and stimulus positions using the eye tracking system, for further assessment of the patients’ performance in tracking the stimulus. The current paper aims to detail the results obtained, revealing relevant results that had not yet been addressed. It was possible to confirm diagnosed visual impairments, and to assess the usability of the RehabVisual platform for monitoring and rehabilitation purposes.